Alana (Keller) Hoey, PhD
@AlanaKelScience
Followers
98
Following
220
Statuses
84
cancer biologist // immunotherapy geek
Denver, CO
Joined November 2021
RT @DanielSherbenou: My-DST result correlates with clinic response in prospective clinical trial #ASH24 #MMSM
0
4
0
0
5
0
RT @CUCancerBio: CONGRATS to Dr. Alana Keller Hoey for successfully defending her thesis today! Way to go Dr. Keller Hoey! #BestYouCANB @Al…
0
3
0
RT @CUCancerBio: Mark your calendar for Alana Keller’s thesis defense next Tuesday! @AlanaKelScience @DanielSherbenou #BestYouCANB
https://…
0
4
0
Our ASH abstract describing a new CD45+LAG-3+ phenotype displayed by myeloma cells persisting after T cell redirection therapies is now live!
0
3
10
RT @CUCancerBio: Mark your calendars for Alana Keller's thesis defense! @AlanaKelScience @DanielSherbenou #BestYouCANB
0
2
0
RT @DanielSherbenou: Out Yesterday! @llamalorraine found that most samples from IMiD Refractory MM have IMiD-induced degradation of Ikaros…
0
3
0
RT @CRC_AACR: #ExVivo Efficacy of SAR442257 anti-CD38 Trispecific T Cell Engager in #MultipleMyeloma Relapsed After Daratumumab and BCMA Ta…
0
2
0
RT @CUCancerBio: CONGRATS to Dr. Lorraine Davis in the @DanielSherbenou lab for successfully defending her thesis today! So proud of all of…
0
1
0
RT @DanielSherbenou: Absolutely nailed it @llamalorraine I’m so incredibly proud of all you have accomplished 🥹
0
2
0
RT @RahulBanerjeeMD: We often talk about recycling CD38s after BCMA CAR-T failure in #MMsm... vs going to T-cell redirection with a differe…
0
6
0
RT @CRC_AACR: Just published: #ExVivo Efficacy of SAR442257 anti-CD38 Trispecific T Cell Engager in #MultipleMyeloma Relapsed After Daratum…
0
3
0
RT @DanielSherbenou: Ex Vivo Screening Comparing Elranatamab Effectiveness Before and After CAR-T. Shout out to ASH abstract lead author @A…
0
1
0